Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Methods Mol Biol. 2022;2573:77-87. doi: 10.1007/978-1-0716-2707-5_7.
Modified mRNA (modRNA) is a safe and effective vector for gene-based therapies. Notably, the safety of modRNA has been validated through COVID-19 vaccines which incorporate modRNA technology to translate spike proteins. Alternative gene delivery methods using plasmids, lentiviruses, adenoviruses, and adeno-associated viruses have suffered from key challenges such as genome integration, delayed and uncontrolled expression, and immunogenic responses. However, modRNA poses no risk of genome integration, has transient and rapid expression, and lacks an immunogenic response. Our lab utilizes modRNA-based therapies to promote cardiac regeneration following myocardial infarction and heart failure. We have also developed and refined an optimized and economical method for synthesis of modRNA. Here, we provide an updated methodology with improved translational efficiency for in vitro and in vivo application.
修饰信使 RNA(modRNA)是一种安全有效的基因治疗载体。值得注意的是,COVID-19 疫苗采用了 modRNA 技术来翻译刺突蛋白,这验证了 modRNA 的安全性。使用质粒、慢病毒、腺病毒和腺相关病毒等替代基因传递方法存在基因组整合、延迟和失控表达以及免疫原性反应等关键挑战。然而,modRNA 不存在基因组整合的风险,具有短暂而快速的表达,并且缺乏免疫原性反应。我们的实验室利用基于 modRNA 的疗法在心肌梗死和心力衰竭后促进心脏再生。我们还开发并完善了一种优化且经济的 modRNA 合成方法。在这里,我们提供了一种改进的体外和体内应用的方法,该方法具有更高的翻译效率。